|
Vaccine Detail
ChAd63-KH |
Vaccine Information |
- Vaccine Name: ChAd63-KH
- Target Pathogen: Leishmania donovani
- Target Disease: Visceral leishmaniasis
- Vaccine Ontology ID: VO_0003961
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: mouse
- Antigen: KH, a self-cleaving polyprotein comprising L. donovani HASPB and KMP-11 Proteins (Osman et al., 2017)
- Immunization Route: Intramuscular injection (i.m.)
- Description: A recombinant vector vaccine for Leishmania donovani that uses an adenovirus 63 viral vector and kH protein (Osman et al., 2017).
|
Host Response |
|
References |
Osman et al., 2017: Osman M, Mistry A, Keding A, Gabe R, Cook E, Forrester S, Wiggins R, Di Marco S, Colloca S, Siani L, Cortese R, Smith DF, Aebischer T, Kaye PM, Lacey CJ. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS neglected tropical diseases. 2017; 11(5); e0005527. [PubMed: 28498840].
|
|